Improved cytotoxic activity toward cell lines and fresh leukemia cells of a mutant anti-CD22 immunotoxin obtained by antibody phage display

Clinical Cancer Research

Volumn 8, Issue 4, 2002, Pages 995-1002

  Salvatore, Giuliana ^a   Beers, Richard ^a   Margulies, Inger ^a   Kreitman, Robert J ^a   Pastan, Ira ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; BACTERIAL TOXIN; CD22 ANTIGEN; HISTIDINE; HYBRID PROTEIN; IMMUNOTOXIN; PLANT TOXIN; PSEUDOMONAS EXOTOXIN; RECOMBINANT PROTEIN; SERINE; THREONINE; TRYPTOPHAN; TYROSINE;

AMINO ACID COMPOSITION; ARTICLE; BINDING AFFINITY; CANCER CELL CULTURE; CANCER IMMUNOTHERAPY; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG EFFICACY; GENE MUTATION; HAIRY CELL LEUKEMIA; HUMAN; HUMAN CELL; LEUKEMIA; LEUKEMIA CELL; LYMPHOMA; MUTAGENESIS; PHAGE DISPLAY; PRIORITY JOURNAL; PROTEIN DOMAIN;

AMINO ACID SEQUENCE; ANTIBODIES, MONOCLONAL; ANTIBODY AFFINITY; ANTIGENS, CD; ANTIGENS, CD22; ANTIGENS, DIFFERENTIATION, B-LYMPHOCYTE; BACTERIOPHAGES; BASE SEQUENCE; CELL ADHESION MOLECULES; CELL LINE; GENE EXPRESSION; GENE LIBRARY; HUMANS; IMMUNOGLOBULIN FRAGMENTS; IMMUNOTOXINS; INHIBITORY CONCENTRATION 50; LECTINS; LEUKEMIA; MUTATION; PLASMIDS; PROTEIN BIOSYNTHESIS; PROTEINS; TUMOR CELLS, CULTURED;

EID: 0036554968     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Greenlee, R. T., Murray, T., Bolden, S., and Wingo, P. A. Cancer statistics, 2000. CA Cancer J. Clin., 50: 7-33, 2000.
2. Brinkmann, U. Recombinant immunotoxins: protein engineering for cancer therapy. Mol. Med. Today, 2: 439-446, 1996.
3. Kreitman, R. J., and Pastan, I. Targeting Pseudomonas exotoxin to hematologic malignancies. Semin. Cancer Biol., 6: 297-306, 1995.
4. Kreitman, R. J., Wilson, W. H., Robbins, D., Margulies, I., Stetler-Stevenson, M., Waldmann, T. A., and Pastan, I. Responses in refractory hairy cell leukemia to a recombinant immunotoxin. Blood, 94: 3340-3348, 1999.
5. Kreitman, R. J., Wilson, W. H., White, J. D., Stetler-Stevenson, M., Jaffe, E., Waldmann, T. A., and Pastan, I. Phase I trail of recombinant immunotoxin Anti-Tac(Fv)-PE38 (LMB-2) in patients with hematologic malignancies. J. Clin. Oncol., 18: 16222-1636, 2000.
6. Tedder, T. F., Tuscano, J., Sato, S., and Kehrl, J. H. CD22, a B lymphocyte-specific adhesion molecule that regulates antigen receptor signaling. Annu. Rev. Immunol., 5: 481-504, 1997.
7. Sausville, E. A., Headlee, D., Stetler-Stevenson, M., Jaffe, E. S., Solomon, D., Figg, W. D., Herdt, J., Kopp, W. C., Rager, H., and Steinberg, S. M. Continuous infusion of the anti-CD22 immunotoxin IgG-RFB4-SMPT-dgA in patients with B-cell lymphoma: a Phase I study. Blood. 85: 3457-3465, 1995.
8. Amlot, P. L., Stone, M. J., Cunningham, D., Fay, J., Newman, J., Collins, R., May, R., McCarthy, M., Richardson, J., and Ghetie, V. A Phase I study of an anti-CD22-deglycosylated ricin A chain immunotoxin in the treatment of B-cell lymphomas resistant to conventional therapy. Blood, 82: 2624-2633, 1993.
9. Vitetta, E. S., Stone, M., Amlot, P., Fay, J., May, R., Till, M., Newman, J., Clark, P., Collins, R., and Cunningham, D. Phase I immunotoxin trial in patients with B-cell lymphoma. Cancer Res., 51: 4052-4058, 1991.
10. Hwang, J., Fitzgerald, D. J., Adhya, S., and Pastan, I. Functional domains of Pseudomonas exotoxin identified by deletion analysis of the gene expressed in E. coli. Cell, 48: 129-136, 1987.
11. Mansfield, E., Chiron, M. F., Amlot, P., Pastan, I., and FitzGerald, D. J. Recombinant RFB4 single-chain immunotoxin that is cytotoxic towards CD22-positive cells. Biochem. Soc. Trans., 25: 709-714, 1997.
12. Mansfield, E., Amlot, P., Pastan, I., and FitzGerald, D. J. Recombinant RFB4 immunotoxins exhibit potent cytotoxic activity for CD22-bearing cells and tumors. Blood, 90: 2020-2026, 1997.
13. Kreitman, R. J., Margulies, I., Stetler-Stevenson, M., Wang, Q. C., FitzGerald, D. J., and Pastan, I. Cytotoxic activity of disulfide-stabilized recombinant immunotoxin RFB4(dsFv)-PE38 (BL22) toward fresh malignant cells from patients with B-cell leukemias. Clin. Cancer Res., 6: 1476-1487, 2000.
14. Kreitman, R. J., Wang, Q. C., FitzGerald, D. J., and Pastan, I. Complete regression of human B-cell lymphoma xenografts in mice treated with recombinant anti-CD22 immunotoxin RFB4(dsFv)-PE38 at doses tolerated by cynomolgus monkeys. Int. J. Cancer, 81: 148-155, 1999.
15. Kreitman, R. J., Wilson, W. H., Bergeron, K., Raggio, M., Stetler-Stevenson, M., FitzGerald, D. J., and Pastan, I. Efficacy of the anti-CD22 recombinant immunotoxin BL22 in classic or variant hairy-cell leukemia resistant to chemotherapy. N. Engl. J. Med., 345: 241-247, 2001.
16. Chowdhury, P. S., and Pastan, I. Improving antibody affinity by mimicking somatic hypermutation in vitro. Nat. Biotechnol., 17: 568-572, 1999.
17. Neuberger, M. S., and Milstein, C. Somatic hypermutation. Curr. Opin. Immunol., 7: 248-254, 1995.
18. Beers, R., Chowdhury, P., Bigner, D., and Pastan, I. Immunotoxins with increased activity against epidermal growth factor receptor vIII-expressing cells produced by antibody phage display. Clin. Cancer Res., 6: 2835-2843, 2000.
19. MacCallum, R. M., Martin, A. C., and Thornton, J. M. Antibodyantigen interactions: contact analysis and binding site topography. J. Mol. Biol., 262: 732-745, 1996.
20. Shen, G. L., Li, J. L., Ghetie, M. A., Ghetie, V., May, R. D., Till, M., Brown, A. N., Relf, M., Knowles, P., and Uhr, J. W. Evaluation of four CD22 antibodies as ricin A chain-containing immunotoxins for the in vivo therapy of human B-cell leukemias and lymphomas. Int. J. Cancer, 42: 792-797, 1988.
21. Johnson, G., and Wu, T. T. Kabat database and its applications: 30 years after the first variability plot. Nucleic Acids Res., 28: 214-218, 2000.
22. Keppler-Hafkemeyer, A., Kreitman, R. J., and Pastan, I. Apoptosis induced by immunotoxins used in the treatment of hematologic malignancies. Int. J. Cancer, 87: 86-94, 2000.
23. Mintz, U., and Sachs, L. Changes in the surface membrane of lymphocytes from patients with chronic lymphocytic leukemia and Hodgkin's disease. Int. J. Cancer, 15: 253-259, 1975.
24. Yelton, D. E., Rosok, M. J., Cruz, G., Cosand, W. L., Bajorath, J., Hellstron, I., Hellstrom, K. E., Huse, W. D., and Glaser, S. M. Affinity maturation of the BR96 anti-carcinoma antibody by codon-based mutagenesis. J. Immunol., 155: 1994-2004, 1995.
25. Barbas, C. F., and Burton, D. R. Selection and evolution of highaffinity human anti-viral antibodies. Trends Biotechnol., 14: 230-234, 1996.
26. Yang, W. P., Green, K., Pinzsweeney, S., Briones, A. T., Burton, D. R., and Barbas, D. F. CDR walking mutagenesis for the affinity maturation of a potent human anti-Hiv-1 antibody into the picomolar range. J. Mol. Biol., 254: 392-403, 1995.
27. Low, N. M., Holliger, P., and Winter, F. Mimicking somatic hypermutation: affinity maturation of antibodies displayed on bacteriophage using a bacterial mutator strain. J. Mol. Biol., 260: 359-368, 1996.
28. Dekruif, J., Boel, E., and Logtenberg, T. Selection and application of human single-chain Fv antibody fragments from a semisynthetic phage antibody display library with designed CDR3 regions. J. Mol. Biol., 248: 97-105, 1995.
29. Morea, V., Tramontano, A., Rustici, M., Chothia, C., and Lesk, A. M. Conformations of the third hypervariable region in the VH domain of immunoglobulins. J. Mol. Biol., 175: 269-294, 1998.
30. Padlan, E. A. Anatomy of the antibody molecule. Mol. Immunol., 31: 169-217, 1994.